Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410950 | 1.00 | KMT2A (0.65) | KMT2AL3MBTL1USP2OPRK1LMNA | |
| SCHEMBL22582397 | 0.84 | USP2 (0.58) | KMT2AL3MBTL1USP2OPRK1LMNA | |
| SCHEMBL22582398 | 0.84 | USP2 (0.58) | KMT2AL3MBTL1USP2OPRK1LMNA | |
| SCHEMBL22582396 | 0.84 | USP2 (0.58) | KMT2AL3MBTL1USP2OPRK1LMNA | |
| SCHEMBL21026882 | 0.84 | KMT2A (0.49) | KMT2AL3MBTL1SMN1; SMN2JAK2JAK1 | |
| SCHEMBL31210696 | 0.83 | L3MBTL1 (0.57) | KMT2AL3MBTL1USP2OPRK1 | |
| SCHEMBL22582415 | 0.81 | KMT2A (0.53) | KMT2AL3MBTL1USP2OPRK1LMNA | |
| SCHEMBL22582416 | 0.81 | KMT2A (0.53) | KMT2AL3MBTL1USP2OPRK1LMNA | |
| SCHEMBL22582413 | 0.81 | KMT2A (0.53) | KMT2AL3MBTL1USP2OPRK1LMNA | |
| SCHEMBL3759046 | 0.80 | L3MBTL1 (0.54) | KMT2AL3MBTL1USP2OPRK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814377-B2 | Pyrimidine compound as JAK kinase inhibitor | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814377-B2 | Pyrimidine compound as JAK kinase inhibitor | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220396573-A1 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-11420965-B2 | Pyrimidine compound as JAK kinase inhibitor | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220009926-A1 | ESTER AND CARBONATE PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-01-13 | — | — | US | disclosed |
| US-20210214349-A1 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-07-15 | — | — | US | disclosed |
| US-10988470-B2 | Pyrimidine compound as JAK kinase inhibitor | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200369660-A1 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200338073-A1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-10-29 | — | — | US | disclosed |
| WO-2020219640-A1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-10-29 | — | — | WO | disclosed |
| US-10774080-B2 | Pyrimidine compound as JAK kinase inhibitor | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200140430-A1 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-05-07 | — | — | US | disclosed |
| US-10562894-B2 | Pyrimidine compound as JAK kinase inhibitor | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190241555-A1 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-08 | — | — | US | disclosed |
| US-10308646-B2 | Pyrimidine compound as JAK kinase inhibitor | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241555-A1 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | KMT2A 1210/4885L3MBTL1 4229/4885USP2 3527/4885 |
| US-20200140430-A1 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | KMT2A 1210/4885L3MBTL1 4229/4885USP2 3527/4885 |
| US-20220396573-A1 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | KMT2A 1210/4885L3MBTL1 4229/4885USP2 3527/4885 |
| US-10562894-B2 | Pyrimidine compound as JAK kinase inhibitor | JAK1, JAK2, JAK3 | KMT2A 1210/4885L3MBTL1 4229/4885USP2 3527/4885 |
| US-20220009926-A1 | ESTER AND CARBONATE PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS | JAK1, JAK3, JAK2 | KMT2A 1613/4885L3MBTL1 4468/4885USP2 4360/4885 |
| US-20200338073-A1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | JAK1, JAK3, JAK2 | KMT2A 1395/4885L3MBTL1 4170/4885USP2 3069/4885 |
| US-11814377-B2 | Pyrimidine compound as JAK kinase inhibitor | JAK1, JAK2, JAK3 | KMT2A 1210/4885L3MBTL1 4229/4885USP2 3527/4885 |
| US-11420965-B2 | Pyrimidine compound as JAK kinase inhibitor | JAK1, JAK2, JAK3 | KMT2A 1210/4885L3MBTL1 4229/4885USP2 3527/4885 |
| US-10774080-B2 | Pyrimidine compound as JAK kinase inhibitor | JAK1, JAK2, JAK3 | KMT2A 1210/4885L3MBTL1 4229/4885USP2 3527/4885 |
| US-20200369660-A1 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | KMT2A 1210/4885L3MBTL1 4229/4885USP2 3527/4885 |
| US-10308646-B2 | Pyrimidine compound as JAK kinase inhibitor | JAK1, JAK2, JAK3 | KMT2A 1210/4885L3MBTL1 4229/4885USP2 3527/4885 |
| US-10988470-B2 | Pyrimidine compound as JAK kinase inhibitor | JAK1, JAK2, JAK3 | KMT2A 1210/4885L3MBTL1 4229/4885USP2 3527/4885 |
| US-20210214349-A1 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | KMT2A 1210/4885L3MBTL1 4229/4885USP2 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.